Neonatal and Maternal Ichthyosiform Dermopathy in Association with Kava Use during Pregnancy.
Dermopathy
Ichthyosis
Kava
Newborn
Pregnancy
Journal
Journal of medical toxicology : official journal of the American College of Medical Toxicology
ISSN: 1937-6995
Titre abrégé: J Med Toxicol
Pays: United States
ID NLM: 101284598
Informations de publication
Date de publication:
05 Jun 2024
05 Jun 2024
Historique:
received:
05
03
2024
accepted:
28
05
2024
revised:
16
05
2024
medline:
6
6
2024
pubmed:
6
6
2024
entrez:
5
6
2024
Statut:
aheadofprint
Résumé
Kava, a substance derived from the Piper methysticum plant, is enjoying a surge in popularity in the United States due to its purported anxiolytic and analgesic effects. Though ichthyosiform dermopathy is a known adverse effect associated with chronic kava exposure in adults, dermopathy in a newborn due to maternal kava use has not yet been described. This is a case of a 41-year-old woman who was taking a combination kava/kratom product throughout her pregnancy. She developed an ichthyosiform dermopathy that resolved after she stopped using the product postpartum. Her male infant had a neonatal course complicated by both neonatal opioid withdrawal syndrome, attributed to maternal kratom and buprenorphine use, as well as a diffuse ichthyosiform rash similar to descriptions of kava ichthyosiform dermopathy in adults. His neonatal course was complicated by Group B streptococcus and Serratia marscecens bacteremia (treated with antibiotics) and seizures (treated with lorazepam and phenobarbital). His rash resolved completely by day of life 22. At 9-month outpatient follow-up, he had no dermatologic abnormalities or rash recurrence. Maternal kava use during pregnancy may cause fetal dermopathy presenting as an acquired ichthyosis. More public education is needed about the potential consequences of kava use, particularly during pregnancy.
Identifiants
pubmed: 38839731
doi: 10.1007/s13181-024-01016-x
pii: 10.1007/s13181-024-01016-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. American College of Medical Toxicology.
Références
White CM. The Pharmacology, Pharmacokinetics, Efficacy, and adverse events Associated with Kava. J Clin Pharmacol. 2018;58(11):1396–405. https://doi.org/10.1002/jcph.1263 .
doi: 10.1002/jcph.1263
pubmed: 29791008
Hannam S, Murray M, Romani L, Tuicakau M. Kava Dermopathy in Fiji: an acquired ichthyosis? Int J Dermatol. 2014;53(12):1490–4. https://doi.org/10.1111/ijd.12546 .
doi: 10.1111/ijd.12546
pubmed: 25069767
Pont-Fernandez S, Kheyfets M, Rogers JM, Smith KE, Epstein DH. Kava (Piper methysticum) in the United States: the quiet rise of a substance with often subtle effects. Am J Drug Alcohol Abuse. 2023;49(1):85–96. https://doi.org/10.1080/00952990.2022.2140292 .
doi: 10.1080/00952990.2022.2140292
pubmed: 36410029
Norton SA, Ruze P. Kava Dermopathy. J Am Acad Dermatol. 1994;31(1):89–97. https://doi.org/10.1016/s0190-9622(94)70142-3 .
doi: 10.1016/s0190-9622(94)70142-3
pubmed: 8021378
Jappe U, Franke I, Reinhold D, Gollnick HP. Sebotropic drug reaction resulting from kava-kava extract therapy: a new entity? J Am Acad Dermatol. 1998;38(1):104–6. https://doi.org/10.1016/s0190-9622(98)70547-x .
doi: 10.1016/s0190-9622(98)70547-x
pubmed: 9448214
Lebot V, Levesque J. The origin and distribution of kava piper methysticum forst. f. piperaceae: a phytochemical approach. Allertonia. 1989;5(2):223–81. https://doi.org/10.2307/23187398 .
doi: 10.2307/23187398
Volgin A, Yang L, Amstislavskaya T, Demin K, Wang D, Yan D, Wang J, Wang M, Alpyshov E, Hu G, Serikuly N, Shevyrin V, de Wappler-Guzzetta E. Abreu M and Kalueff A. DARK classics in Chemical Neuroscience: Kava. ACS Chem Neurosci 2020 Jan 21. https://doi.org/10.1021/acschemneuro.9b00587 .
Ruze P. Kava-induced dermopathy: a niacin deficiency? Lancet. 1990;335(8703):1442–5. https://doi.org/10.1016/0140-6736(90)91458-m .
doi: 10.1016/0140-6736(90)91458-m
pubmed: 1972218
Tetro N, Moushaev S, Rubinchik-Stern M, Eyal S. The placental barrier: the Gate and the fate in drug distribution. Pharm Res. 2018;35(4):71. https://doi.org/10.1007/s11095-017-2286-0 .
doi: 10.1007/s11095-017-2286-0
pubmed: 29476301
Powell LR, Ryser TJ, Morey GE, Cole R. Kratom as a novel cause of photodistributed hyperpigmentation. JAAD Case Rep. 2022;28:145–8. https://doi.org/10.1016/j.jdcr.2022.07.033 .
doi: 10.1016/j.jdcr.2022.07.033
pubmed: 36187435
pmcid: 9523091